FDA approves first AI test to guide breast cancer chemotherapy decisions
Posted:
According to estimates from 2022, about 2.3 million females around the world were newly diagnosed with breast cancer..The U.S. FDA recently cleared the ArteraAI Breast digital pathology-based risk stratification tool to help doctors predict the likelihood of metastasis in patients with early-stage HR+/HER2- breast cancer to help determine the intensity of their treatment.
GIANT Health is delighted to welcome CareLoop to GIANT Health 2026 as part of the NHS Innovation Accelerator (NIA) Pavilion, where the team will demonstrate how remote monitoring is helping people living with severe mental illness remain well in their…
GIANT Health is delighted to welcome RealBirth to GIANT Health 2026, where the team will showcase how digital innovation is helping transform antenatal education and support more equitable maternity care across the NHS.
Access to high-quality antenatal education plays a…
Attendees
Sponsors and Exhibitors
Contact us